Application 085417

Type
ANDA
Sponsor
CHARTWELL RX

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001PHENTERMINE HYDROCHLORIDEPHENTERMINE HYDROCHLORIDECAPSULE;ORAL30MGNoNo

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A085417-001PHENTERMINE HYDROCHLORIDEPHENTERMINE HYDROCHLORIDE30MGCAPSULE / ORALApproved before 1982

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDENorthwind Health Company, LLC5528d9f7-45ad-d323-e063-6394a90a3e092026-06-25Warnings, Adverse reactionsName fallback
PHENTERMINE HYDROCHLORIDEPHENTERMINE HYDROCHLORIDEAurolife Pharma LLC5927e0f6-3de3-4885-a633-5b92003f6fe42026-06-10Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEPD-Rx Pharmaceuticals, Inc.19f1ce79-65f4-4bf4-a9ff-6ca0a131530f2026-06-02Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEPD-Rx Pharmaceuticals, Inc.130e6087-0ab6-4456-a781-d370f363dc382026-06-01Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDECalvin Scott & Co., Inc.d24aaa53-9c78-4c1b-9495-c785a9cf2b262026-05-21Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDECalvin Scott & Co., Inc.2f3b738f-d66b-40c1-8e69-bcd50bce3e472026-05-21Warnings, Adverse reactionsName fallback
Phentermine hydrochloridePHENTERMINE HYDROCHLORIDECalvin Scott & Co., Inc.3d1d4dde-1c7f-4a20-b8f8-897b1b284f802026-05-21Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEBryant Ranch Prepackd95e14f7-a46d-47fa-8dab-ee3d8d4c7b6d2026-05-12Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEBryant Ranch Prepacke6939fcf-3db2-492a-99ed-a384cdeea7a22026-05-11Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEPD-Rx Pharmaceuticals, Inc.eae1d7f9-733c-434b-9199-5f7052e541da2026-04-14Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEBryant Ranch Prepack328d6a39-34f4-4b74-a1bf-6ec6005b13222026-04-01Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEPD-Rx Pharmaceuticals, Inc.b425840f-380e-42bd-852a-6ee3641977ce2026-03-23Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEBryant Ranch Prepacke48feec6-50c9-4ccd-b9da-56956d14c8532026-03-18Warnings, Adverse reactionsName fallback
Phentermine hydrochloridePHENTERMINE HYDROCHLORIDEBryant Ranch Prepack9155edf8-ea1d-458f-b2a7-e0303fd83cc02026-03-16Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEA-S Medication Solutionsc53bd3c5-01f6-4a21-9e3c-aa4969a01b4b2026-03-04Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDECalvin Scott & Co., Inc.aa9d7161-cda3-4ded-8d5b-424abd1a66812026-02-05Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEBryant Ranch Prepackfa5de92d-a5bf-4ae1-8e13-ad827aeebea32026-02-04Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEA-S Medication Solutions86ec6b9d-2934-4bad-8a80-0b60e2f912f32026-01-24Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEA-S Medication Solutionsea798229-fc2d-417c-9bc9-a3b942f0b64b2026-01-23Warnings, Adverse reactionsName fallback
Phentermine HydrochloridePHENTERMINE HYDROCHLORIDEA-S Medication Solutions0e893b62-bb07-4984-9f0a-3601435fbc272026-01-22Warnings, Adverse reactionsName fallback

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Coadministration with other drugs for weight loss is not recommended (safety and efficacy of combination not established). ( 5.1 ) Rare cases of primary pulmonary hypertension have been reported. Phentermine should be discontinued in case of new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema. ( 5.2 ) Rare cases of serious regurgitant cardiac valvular disease have been reported. ( 5.3 ) Tolerance to the anorectic effect usually develops within a few weeks. If this occurs, phentermine should be discontinued. The recommended dose should not be exceeded. ( 5.4 ) Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. ( 5.5 ) Risk of abuse and dependence. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. ( 5.6 ) Concomitant alcohol use may result in an adverse drug reaction. ( 5.7 ) Use caution in patients with even mild hypertension (risk of increase in blood pressure). ( 5.8 ) A Reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. ( 5.9 ) 5.1 Coadministration with Other Drug Products for Weight Loss Phentermine is indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended. 5.2 Primary Pulmonary Hypertension Primary Pulmonary Hypertension (PPH) – a rare, frequently fatal disease of the lungs – has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patien...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are described, or described in greater detail, in other section: Primary pulmonary hypertension [ see Warnings and Precautions ( 5.2 ) ] Valvular heart disease [ see Warnings and Precautions ( 5.3 ) ] Effect on the ability to engage in potentially hazardous tasks [ see Warnings and Precautions ( 5.5 ) ] Withdrawal effects following prolonged high dosage administration [ see Drug Abuse and Dependence ( 9.3 ) ] The following adverse reactions to phentermine have been identified: Cardiovascular: Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events. Central Nervous System: Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis. Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Allergic: Urticaria. Endocrine: Impotence, changes in libido. Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact KVK-TECH, Inc., at 1-800-862-3895 or customerservice@kvktech.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.